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Acute and Subchronic Toxicity
of Ethylene Glycol Monobutyl Ether
by Tipton R. Tyler*
The available information on the acute and subchronic toxicity of ethylene glycol monobutyl ether is
reviewed. Data from animal studies have been examined from the standpoint ofdose-response relationships
and the sensitivity of various animal species, including man, to the effects of this chemical. In view of
recent findings with other chemically related glycol ethers, particular attention has been given to possible
adverse effects on blood and testicular tissue. In evaluating the hazard that this chemical may pose to man,
consideration has been given to likely routes ofexposure and its irritant properties. It is concluded thatthe
available information continues to support the current ACGIH TWA8-TLV of 25 ppm with a STEL of 75
ppm.
Introduction
Ethylene glycol monobutyl ether (EGBE) has been
studied extensively with respect to establishing expo-
sure conditions at which adverse health effects are
unlikely to occur in humans. Information obtained in
these studies has defined the major organs and tissues
affected by EGBE, established differential response of
various laboratory animal species, and provides a clear
picture ofdose-response relationships by various routes
of exposure. In this paper, the acute toxicity of EGBE
and the effects of repeated exposure by oral admin-
istration, inhalation of vapor and application to the
skin are reviewed. Recent interest in the toxicity of
monoalkyl glycol ethers has centered around effects on
blood forming tissues and the testes. Therefore, obser-
vations in some of the previous studies have been
reevaluated, paying particular attention to detecting
effects on these possible target tissues.
In attempting to assess the potential hazards of
EGBE to humans, the available toxicology information
clearly needs to be evaluated in terms of probable
routes of exposure. Therefore, emphasis has been
placed on studies conducted in laboratory animals by
dermal application and vapor inhalation. Although the
vapor pressure of EGBE (0.6 mm Hg) is lower relative
to that of ethylene glycol monomethyl (EGME) or
monoethyl (EGEE) ether(6and4 mmHg, respectively),
inhalation remains one of the predominant routes of
exposure due to some of the major end uses, i.e.,
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coatings applications. Skin is also a potential significant
route ofhuman exposure, through contact with various
cleaning solutions formulated with EGBE. Ingestion,
on the other hand, is an unlikely primary route ofentry
for humans; exceptions include instances of accidental
poisoning or attempts at suicide. However, there appear
to be no reports of human ingestion of EGBE.
Acute Toxicity
The acute (single dose) lethal toxicity of EGBE has
been determined in a number of laboratory animal
species (Table 1). Rabbits appear to be the most
susceptible to the acute induced effects ofthis material
followed by mice, guinea pigs and rats (1). Carpenter et
al. (1) suggested that the wide intraspecies variation
reported for LD50 values in rats correlates with the
apparently greater susceptibility of older animals as
compared to younger animals, which are four to five
times more resistant to the effects ofsingle oral EGBE
administration.
EGBE is readily absorbed across the skin as indi-
cated by its lethaltoxicity in dermal application studies.
Again, rabbits appear to be more susceptible to the
toxic effects ofthis chemical at alowerdosage levelthan
rats, when applied to the skin. Although quantitative
data are not available, it is relevant that Saparamedov
(5) submerged the tails ofmice (up to two-thirds oftheir
lengths) into undiluted EGBE for 2-hr periods. No
death, adverse systemic effects or skin irritation was
reported.
The effects of a single inhalation exposure to EGBE
to different animal species are shown in Table 2. Again,T. R. TYLER
Table 1. Acute toxicity and primary irritancy of EGBE.
Species
Single oral LD50, mg/kg
Rat 530 to 3000
1480
620
2680
Rabbit 320 to 370
Mouse 1230
1170 to 1700
1000 to 1600
Guinea pig 1200
Single percutaneou:
LD50, mL/kg
Rat
Rabbit
Primary irritation,
Rabbit
Mice
5
2.52 (4 hr)
0.45 to 2.00 (24 hr)
0.63 (24 hr)
0.11 (8 hr)
skin
Mild irritation
Mild irritation (grade 2 of 10)
Mild irritation
Primary irritation, eye
Rabbit Severe (grade 8 of 10)
Moderate (grade 4 of 10)
Reference
(1)
(2)
(3)
(4)
(1)
(1)
(3)
(5)
(1)
(7)
(1)
(4)
(6)
(3)
(4)
(5)
(4)
(8)
there is variability in the data, particularly with
respect to the response of rats. Substantially satu-
rated vapor, which approaches a concentration of 1300
ppm (5), killed only one of six rats after an 8-hr
exposure, while a single exposure to a concentration of
375 ppm produced complete mortality in a group of
older animals. Again, this variability has been attrib-
uted to the greater susceptibility of older animals.
A consideration of the data from these studies
indicates that EGBE presents a slight to moderate
acute hazard to man by single skin contact or by
swallowing. Results of acute inhalation studies indicate
EGBE to be of moderate toxicity. However, its rela-
tively low vapor pressure and good warning properties,
discussed by Carpenter et al. (1), diminish the inhala-
tion hazard when handled under most foreseeable
situations.
Primary Irritation
EGBE is only mildly irritating to rabbit skin when
applied and left uncovered for a 4-hr period. However,
more prolonged exposure to the undiluted chemical, as
encountered in 24-hr percutaneous toxicity studies,
can lead to moderate irritation characterized by ery-
thema, edema and necrosis (4).
There is conflict with regard to reports on the effects
of EGBE on the eye. Early work by Carpenter and
Smyth (8) indicated that the chemical produced only
moderate irritation when 0.02 mL was instilled into the
conjunctival sac; the response was graded 4 out of a
possible maximum of 10. In a more recent study (4),
instillation of0.005 mL into rabbit eyes produced severe
corneal injury with iritis. Moderate corneal injury was
observed when 0.5 mL of a 15% aqueous dilution was
Table 2. Effects of single vapor exposure of EGBE to
laboratory animals.
Exposure
level, ppm Response Reference
2400 8 hr: killed 8 of 8 rats (9)
Substantially Rats: LT50 = 9 hr (1)
saturated vapor Guinea pigs: LT50 = 7 hr (10)
( 4300)
800 8 hr: killed 3 of 6 rats (1)
4 hr: killed 0 of 6 rats
700 7 hr: LC50 for mice (11)
500 8 hr: killed 0 of 6 rats (1)
4 hr: killed 1 of 6 rats
375 7 hr: killed 11 of 13 (1)
and 23 of 23 older rats
instilled into the eye, and no injury was noted from a 5%
aqueous dilution. Based on these observations, the
material was graded 8 on the 10-point scale.
Repeated Oral Administration
Results ofthree studies in which EGBE was adminis-
tered repeatedly by mouth to rats or mice are given in
Table 3. In an early rat study conducted by Carpenter
and Pozzani (12), decreased weight gain was noted at
dosage levels of 1500 or 300 mg/kg administered in feed
for 90 days. An increase in the relative liver and kidney
weight was reported at 1500 mg/kg, and in relative liver
weight at 300 mg/kg. The value ofthis study is limited
by a high mortality in all treatment and control groups,
probably caused by a high incidence ofpneumonia. It is
ofinterest to note that when pooled urine from rats fed
EGBE at 1500 or300mg/kgfor3 or6days wasanalyzed
by a benzidine test, no hemoglobin was detected.
In a second study (13) decreased weight gain and
increased relative liver and kidney weights were re-
ported at 950 mg/kg. In addition, testicular atrophy was
reported at 950 and 200 mg/kg. The sections of testes
from this studyhavebeenrecentlyreviewed and confirm
a treatment-related degeneration and atrophy of the
seminiferous tubules. The lesion was present at 950 and
200 mg/kg, but not in those animals receiving EGBE at
40 or 8 mg/kg. The EGBE used in this study was
manufacturedusingborontrifluoride(BF3) asacatalyst,
a process which has not been used forthe past 15 years.
EGBE so produced is known to contain a number of
impurities not found in current production material
(16); these include crown ethers, which have been
shown to produce testicular atrophy with degeneration
of the germinal epithelium (17), and fluoroethanol.
More recently, mice were given EGBE by gavage over
a 5-week period at dosages of2000, 1000 and 500 mg/kg
(14,15). At 2000 mg/kg all the animals died. This finding
is consistent with the acute toxicity data presented in
Table 1, which indicates thatthe acute oral LD50 in mice
lies between 1000 and 1700 mg/kg. In the mice receiving
the test chemical at 1000 and 500 mg/kg, erythrocyte
counts were statistically significantly decreased, but
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Table 3. Effects of repeated peroral administration of EGBE in rats and mice.
Dosage
Experimental concentration,
Species design mg/kg Significant effects Reference
Rats 5/sex/dosage group 1500 Decreased body weight gain; increased relative liver and (12)
EGBE in feed daily kidney weights
for 90 days 300 Increased relative liver weight
80 No observable effects
20 No observable effects
Rats 10/sex/dosage group 950 Decreased body weight gain; increased relative liver (13)
EGBE in feed daily and kidney weights; seminiferous tubule degeneration
for 91 to 93 days 200 Decreased weight gain in males, seminiferous tubule
degeneration
40 No observable effects
8 No observable effects
Mice 5 males/dosage group 2000 Complete mortality (14,15)
administered by 1000 1 of 5 with testicular atrophy, depressed erythrocyte count
gavage 5 days/week 500 Depressed erythrocyte count
for 5 weeks
there was no statistically significant effect on white
blood cell counts, or on body, testicular, liver or kidney
weights. In the 1000 mg/kg group one of five mice
demonstrated seminiferous tubular atrophy.
The data taken from these studies indicate that
repeated oral administration of EGBE will produce
adverse effects on the liver, kidney and erythrocytes. It
is not clear whether the chemical which is available by
current production processes is capable of producing
damage to testicular tissues when administered orally.
The available data concerning this effect is equivocal
with respect to sample purity and a lack ofresponse by
other routes of administration. The lowest dosage at
which any adverse effect was noted was 200 mg/kg in
the rat (testicular effects) and 500 mg/kg in the mouse
(decreased RBC). The no-observable effect level in rats
was 80 mg/kg.
Repeated Inhalation Exposure
Results of repeated inhalation exposures conducted
invariouslaboratoryanimalspecies, alongwithobserva-
tions from brief human exposures, are given in Table 4.
The predominant effects observed in rats include re-
duced body weight gain, hematological changes and
increased absolute andrelative kidneyand liverweights.
In some ofthe earliest work with this chemical, Werner
and co-workers identified the red blood cell as one ofthe
more sensitive indicators oftoxicity (20). Using in vitro
methodology, these workers demonstrated that erythro-
cytes became extremely susceptible to osmotic hemoly-
sisin the presence oflow concentrations ofthe chemical.
This observation was confirmed by extensive in vivo
studies conducted by Carpenter and his co-workers (1),
who demonstrated erythrocyte fragility in the rat,
mouse and rabbit after exposure to EGBE, but could
not demonstrate the effect in the monkey, dog, guinea
pig or human. The lowest exposure level at which
erythrocyte fragility was detected in rats was 62 ppm,
while no effect was noted at 32 ppm. Erythrocyte
fragility, at least in mice, appeared to be transient
with the effect being noted immediately after a 7-hr
exposure, but with recovery during the 17-hr period
between exposures. Mice did not develop a tolerance,
since the effect of EGBE on the erythrocyte was as
great after the 89th exposure as it was after the first
exposure.
The hemolytic effect ofEGBE appears to be responsi-
ble for the transient hemoglobinuria, or red discolored
urine, noted during the first few days of several of the
animal studies. In all studies where hemoglobinuria has
been noted, it seldom persisted beyond 3 to 5 days of
exposure. Increased liver and kidney weights have also
been noted at higher exposure levels. This effect
appears to be reversible with absolute or relative organ
weights returning to values similar to those in control
animals after arecovery period as short as 1 week. In no
case did exposure to EGBE vapor produce decreased
testicular weight. Histological examination was con-
ducted on testes of rats exposed to concentrations as
high as 250 ppm for 30 exposures (12) and more recently
to 77 ppm for 90 days (19), and onthe testes from guinea
pigs exposed at a concentration of 500 ppm for 30 days
(1), a dog exposed to 385 ppm and a monkey exposed to
100 ppm (21). In no case was there any evidence of
treatment-related testicular pathology.
In rats, the lowest exposure concentration of EGBE
which produced any adverse effect was 62 ppm, where
erythrocyte fragility was increased. Exposure to 77
ppm produced transient decreases in weight gain and
erythrocyte count with complete recovery by the com-
pletion of the 90-day exposure period. The no observ-
able effect level in rats was 32 ppm. No effects were
observed in guinea pigs exposed to 125 ppm, but
increased erythrocyte fragility was detected in mice
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Table 4. Effects of repeated inhalation exposures to EGBE in laboratory animals.
Dosage
Experimental concentration,
Species design mg/kg Significant effects Reference
Rats 23/exposure concentrations for 5 hr/day, 320 Decreased erythrocyte count and Hb (18)
5 days/week; groups killed at 1, 3,
or 5 weeks of exposure and at 1 week
post-exposure
Rats 15/sex/exposure concentration for 7
hr/day for 5 days/week for 30
exposures
Rats 4/sex/exposure concentration for 6
hr/day for 15 exposures
Rats 7 to 8/sex exposure concentration for 6
hr/day, 5 days/week for 9 exposures
over 11 days with one of two groups
exposed to 245 ppm killed at 14 days
post-exposure
Rats 16/sex/exposure concentration for 6
hr/day, 5 days/week with groups killed
at 5 and 13 weeks of exposure
Guinea pigs 10 males/exposure concentration for 7
hr/day, 5 days/week for 6 weeks
Guinea pigs 10 males/exposure concentration for 7
hr/day, 5 days/week for 6 weeks
Mice 70 males/exposure concentration for 7
hr/day, for 5 days/week, with groups
killed at 6, 12, and 18 weeks of
exposure and at 6 weeks post-exposure
Dogs 2 exposed 5 hr/day for 5 days/week for
12 weeks and killed 5 weeks post-
exposure
Humans 3 to 4 subjects exposed for two 4-hr
periods with 30 min rest period
between exposures
concentration; increased reticulocytes;
Recovery during post-exposure period
135 Decreased erythrocyte count and Hb
concentration; increased reticulocytes;
recovery during week 3-5 of exposure
250 Hemoglobinuria in both sexes after first
3 exposures; increased relative liver and
kidney weight
125 Increased relative liver and kidney weights
62 No observable effects
100 Increased erythocyte fragility
50 No observable effects
20 No observable effects
245 Decreased weight gain; hemoglobinuria; decreased
erythrocyte count and Hb concentration;
increased reticulocytes and nucleated RBC;
increased liver weight; substantial recovery of
erythroid values during 14 day recovery;
complete recovery of liver weight
86 Decreased body weight gain in females; decreased
erythrocyte count and Hb concentration;
increased reticulocytes and nucleated
erythrocyte count
20 No observable effects
77 Transient decrease in weight gain of females;
decrease in erythrocyte count in females at 6
weeks but not at 13 weeks of exposure
25 No observable effects
5 No observable effects
250 Increased kidney weight
125 No observable effects
62 No observable effects
500 Increased mortality; decreased body weight
375 Increased mortality; decreased body weight
gain; increased kidney weight
400 Increased erythrocyte fragility; hemoglobinuria
during first 3 exposures; increased liver weight
with recovery during post-exposure
200 Increased erythrocyte fragility; hemoglobinuria
during first 3 exposures; increased liver weight
after 6 weeks of exposure with recovery during
post-exposure
100 Increased erythrocyte fragility
415 Signs of respiratory and eye irritation; decreased
erythrocyte count and Hb concentration;
increased blood urea
200 Nose, throat and eye irritation with taste
disturbances; headache
100 Nose, throat and eye irritation with taste
disturbances; nausea
(12)
(9)
(19)
(19)
(12)
(1)
(1)
(20)
(1)
exposed to 100 ppm. Humans found both 200 ppm and
100 ppm intolerable due to irritancy.
Repeated Dermal Exposure
The results from two repeated skin application stud-
ies conducted with New Zealand rabbits are summa-
rized in Table 5. In a 9-day study, EGBE was applied to
the clipped skin of the animals under an occlusive
dressing (22). Different doses were achieved by apply-
ing a constant volume of varying concentrations of
aqueous dilutions of the test material. Applications
were made for 5 consecutive days followed by a 2-day
recovery period and then four additional applications
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were made. The animals were killed 14 days after the
ninth application.
Significant findings included decreased rate of body
weight gain in the female rabbits dosed with undiluted
material. These animals also exhibited a decreased
erythrocyte count, hemoglobin (Hb) concentration,
mean corpuscular Hb concentration and an increase in
the mean corpuscular Hb. Hemoglobinuria was noted in
male and female rabbits treated with undiluted EGBE
and in females treated with 50% aqueous dilution.
Erythema and edema were noted at the site ofapplica-
tion of the test material in all animals dosed with the
undiluted chemical. Necrosis also developed in these
animals by the sixth study day. In those receiving the
50% aqueous dilution, erythema and edma were also
present with necrosis developing in one of five males
and four of five females. Only mild indications of skin
irritation were reported in the lower two dosage level
groups in which 25%, or 5% aqueous dilutions ofEGBE
were applied. There were no differences in the weight
gain of male animals at any dosage level. In addition,
there were no differences in the absolute or relative
weights of organs between the treated male or female
rabbits at any dosage leveland the controls. Ofnote was
one female rabbit treated with undiluted EGBE killed
in extremis on the fifth treatment day. The moribund
condition of this animal could not be attributed to
EGBE application.
Based on the results of the 9-day study, a 13-week
(subehronic) study was conducted under sponsorship of
the Chemical Manufacturers Association. Dosage levels
were 150, 50 and 10 mg/kgbodyweight (23). In order to
ensure a relatively constant surface area coverage of
test material, aqueous dilutions were prepared which
would allow approximately 1 mL of solution to supply
the appropriate quantity ofEGBE, i.e., 42.8% 14.3% or
2.8%. The diluted test material was applied under a
poly (vinylidene chloride) wrap to the clipped skin of
10 rabbits of each sex for each dosage group. Applica-
tions were made 6 hr/day for 5 days/week. The animals
remained unrestrained both during and after exposure.
No EGBE-induced changes were noted with respect
to clinical observations, skin irritation, body weight,
body weight changes, food consumption, hematology
values, red blood cell fragility, differential white blood
cell counts, serum chemistry, organ weights, final body
weights orrelative organ weights. The only microscopic
pathological changes noted in animals of all groups,
including the control, were related to subelinical para-
sitic or bacterial infections. Four animals were either
found dead or killed in extremis during the study for
causes unrelated to treatment. These included: one
male from the high dose group found dead on study day
92 from encephalitozoonosis; one female in this group
killed on study day 32 after suffering a broken back; a
male rabbit in the 50 mg/kg group found dead on study
day 15, attributed to agastriculcer; andfinally, afemale
in the 10 mg/kg dosage group found dead due to
pasteurellosis on study day 96.
In summary, the two studies show that adverse
systemic effects from dermal application of EGBE to
rabbits would appear to be dependent both on the
concentration applied and the dosage level employed.
The lowest level at which effects were noted was 180
mg/kg applied as a 50% aqueous dilution, where hemo-
globinuria was noted in female rabbits. The highest
no-observable level for systemic effects was 150 mg/kg
applied as a 43% solution. Indeed, at this dosage level
no increased incidence of skin irritation was noted.
Discussion
Over a number of years, extensive animal testing of
EGBE has provided information which may be used to
evaluate the potential for adverse effects in exposed
humans. The most sensitive index of toxicity is the
effect on the red blood cell, although liver and kidney
are also implicated as target organs. EGBE would
Table 5. Effects of repeated application of EGBE to the skin of rabbits.
Experimental
design
5/sex/dosage concentration treated with 1 mL of
100%, 50% 25% or 5% solutions ofEGBE under
an occlusive dressing 5 days/week for 6 hr/day
for 9 applications over 11 days; 14 day
observation period after final application
10/sex/dosage level treated with 1 mL of 43%,
14% or 3% solutions of EGBE under an
occlusive dressing; 5 days/week, 6 hr/day for
13 weeks
Dosage
concentration,
mg/kg
360
(undiluted)
180
(50%)
90
(25%)
18
(5%)
150
(43%)
50
(14%)
10
(3%)
Significant effects
Decreased body weight gain and erythropoietic
values in females; hemoglobinuria in males and
females; erythema, edema and necrosis at site
of application; recovery at end of 14-day
observation period
Hemoglobinuria in females; erythema, edema and
necrosis at site of application
Mild skin irritation
Mild skin irritation
No observable systemic effects
No observable effects
No observable effects
Reference
(22)
(23)
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appear to have a specific effect on the erythrocyte
membrane, causing the cell to become more fragile and
have anincreased susceptibility to osmotic hemolysis. It
is likely that in exposed animals this increased cellular
fragility leads to intravascular hemolysis which is re-
sponsible for the hemaglobinuria noted in several ani-
mal studies. Urine discoloration noted in these studies
was transient in nature. Carpenter et al. (1) suggested
that it was only the older erythrocytes which were
susceptible to the effects ofEGBE, and that after a loss
of these cells due to lysis during initial exposures, a
younger and less susceptible cell population would be
established. It is possible that the early hemoglobin-
uria may have played a role in the pathogenesis of the
kidney damage reported in some EGBE animal toxicity
studies (24).
Increased liver and kidney weight, particularly when
expressed as a percentage ofbody weight, has been the
only other organ finding in laboratory animals exposed
to EGBE.
Although there has been one report of testicular
damage arisingfrom ingestion ofEGBE (12), this result
is considered suspect for several reasons. First, the test
chemical may have contained impurities known to pro-
duce testicular damage. Second, in a further and more
detailed gavage study no statistically significant de-
crease in testicular weight or increased incidence of
germinal epithelial cell damage was obtained (15).
Third, testicular effects have not been seen in labora-
tory animals administered EGBE by other routes i.e.,
inhalation or dermal exposure. Although there is no
analytical data on the test material, it is likely that the
effects produced in testes were the result of impurities
found in EGBE manufactured by a process which is no
longer in use.
The acute percutaneous toxicity of EGBE indicates
that it is readily absorbed across the skin. The dosage
levels at which adverse effects are observed, however,
appear to be influenced by the concentration of the
chemical in the aqueous dilutions employed in the tests.
This suggests that watermay influence the ability ofthe
chemical to pass through the skin barrier. However, it
has been noted that no discernible liquid remains on the
skin at the end ofa 6 hr exposure. Therefore, additional
studies may be required to clarify the effect ofaqueous
dilution on the skin permeability of EGBE and other
glycol ethers.
Conclusions
EGBE has been tested for its potential to produce
adverse effects in laboratory animals by ingestion,
vapor inhalation and skin penetration. The lowest
dosage level at which effects were noted by ingestion
was 200 mg/kg for 90 days, which produced testicular
effects in rats, and 500 mg/kg for 5 weeks in mice where
a decrease in erythrocyte count was noted. The
significance ofthe testicular effect is uncertain because
of the possibility that impurities were present in the
test sample which are known to produce germinal
epithelial cell damage. A no-observable effect level of80
mg/kgwas obtained inrats which received the EGBE in
feed for 90 days. The lowest vapor exposure concentra-
tion at which effects were noted was 62 ppm (RBC
fragility). Female rats exposed to 77 ppm for 13 weeks
exhibited transient decreased weight gain and a tran-
sient decrease in erythrocyte count. An exposure con-
centration of 100 ppm produced increased erythrocyte
fragility in mice. The no-observable effect level in rats
exposed for 13 weeks was 25 ppm and in guinea pigs
exposed for 6 weeks was 125 ppm. A dosage concentra-
tion of 180 mg/kg applied as a 50% aqueous dilution to
the skin offemale rabbits fornine applications produced
hemoglobinuria. No observable systemic effects were
noted when 150 mg/kg was applied to the skin ofrabbits
for 13 weeks.
Although the rabbit appears to be the most sensitive
species with regard to the acutely induced effects of
EGBE, the rat is more susceptible to repeated expo-
sures and to effects on the erythrocyte. The dog, guinea
pig, monkey and man are resistant to the effects ofthis
chemical on the erythrocyte. Vapor concentrations of
200 and 100 ppm produce nasal, respiratory and eye
irritations of approximately the same degree. It is
unlikely that humans would tolerate exposure levels of
100 ppm for prolonged periods of time.
The available information on the acute and repeated
exposure toxicity of EGBE to laboratory animals and
man accords with the current ACGIH Threshold Limit
Value (TWA8) of25 ppm and ashort-term exposure limit
of 75 ppm.
The author would like to express his sincere appreciation to
Dr. Robert H. Garman for the microscopic evaluation of testicular
tissuereviewed from some oftheolderstudiesand to Dr. Bryan Ballan-
tyne for his continued encouragement and editorial review of the
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